Review Article

Impact of HPV in Oropharyngeal Cancer

Linda Marklund and Lalle Hammarstedt

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, 171 76 Stockholm, Sweden

Correspondence should be addressed to Linda Marklund, linda.marklund@karolinska.se and Lalle Hammarstedt, lalle.hammarstedt@karolinska.se

Received 31 August 2010; Accepted 21 November 2010

Copyright © 2011 L. Marklund and L. Hammarstedt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The incidence of oropharyngeal cancers has increased in the western world and Human Papilloma Virus (HPV) has been recognized as a risk factor in the last decades. During the same period the prevalence of HPV in oropharyngeal tumours has increased and HPV has been suggested responsible for the increase. The HPV-positive tumours are today recognized as a distinct subset of head and neck cancers with its own clinopathological and risk profile and have a significantly improved prognosis regardless of treatment strategy. This review summarizes current knowledge regarding human papillomavirus biology, oncogenic mechanisms, risk factors, and impact of treatment.

1. Introduction

Head and neck squamous cell carcinoma is the sixth most common cancer worldwide [1]. The incidence of head neck cancers varies widely around the world and even within populations. Oral and oropharyngeal cancer constitutes 3–5% of the malignancies in Europe, while this figure in parts of Southeast Asia and India reaches up to 40–50% [2–4]. Eighty to ninety percent of head and neck cancer cases are considered to be associated with known risk factors, such as smoking, betel nut chewing, and alcohol abuse [4, 5].

The prognosis for HNSCC is generally low in the more advanced stages and there has been only a modest improvement in recent years and the treatment frequently sentences the patient to life-long sequelae such as difficulties with swallowing, dryness of the mouth, esophageal strictures, and osteoradionecrosis. Head and neck cancer is a heterogeneous group that differs greatly in tumour aggressiveness and response to treatment. The treatment is today based on tumour stage which thus leads to suboptimal outcome for some patients. The identification of predictive markers is urgent to enable optimization of treatment and reduction of sequelae for the individual patient.

Despite a decreasing incidence of head and neck squamous cell carcinoma in general, attributed to a decrease in the prevalence of smoking [6], the incidence of oropharyngeal SCC is rising [7–12]. Human papillomavirus (HPV) has for some time been suggested to be involved in the carcinogenesis of oropharyngeal cancer. The Agency for Research on Cancer (IARC) now recognizes HPV as a risk factor for oropharyngeal cancer, and accumulating molecular and epidemiological data now show that high-risk types of HPV are responsible for a subset of oropharyngeal cancer [13–15]. HPV-positive cancers cases are now in majority in the western world and these tumours are also shown to have better outcome than the HPV-negative patients. However, the natural history and the tumour development biology of HPV-infection in head and neck tumours are not yet fully understood and the best management needs further investigation and clinical trials in order to achieve the best clinical outcome for the patients with HPV-positive head and neck tumours.

2. Human Papilloma Virus (HPV) and Tumour Biology

HPV was first identified in 1949 [16] and today over 100 different HPV types have been characterized [17]. HPVs are small, circular double stranded DNA viruses with a genome that consists approximately 8000 base pairs. HPV infection
is highly restricted to basal cells in the mucosal or epithelial layers. Replication occurs within the nucleus of the infected cell and is dependent on S-phase entry since it requires the DNA machinery [18]. The HPV subtypes are divided into high-risk and low-risk HPV regarding their malignant potential. Approximately 15 high-risk subtypes are known but only HPV subtypes 16, 18, 31, 33, and 35 have been identified playing a role in the development of oropharyngeal head and neck cancer. HPV 16 is the far most common type detected in oropharyngeal cancer accounting for 90–95% of the HPV positive tumours [19].

High-risk HPVs produce 2 oncoproteins, E6 and E7, which are necessary for viral replication through their proliferation stimulating activity and play a key role in malignant transformation and maintenance. The E6 oncoprotein binds and induces the degradation of the p53 tumour suppressor protein via an ubiquitin-mediated process disrupting the p53 pathway which leads to uncontrolled cell cycle progression [20, 21]. The HPV E7 protein binds and degrades the retinoblastoma protein (pRb), preventing it from inhibiting the transcription factor E2F resulting in loss of cell cycle control. Furthermore, the functional inactivation of Rb results in upregulation of the p16-protein. P16 is encoded by the CDKN2A tumour suppressor gene and regulates the activity of CyklmD-CDK4/6 complexes that phosphorylate Rb leading to release of the transcription factor E2F which initiates cell cycle progression. The bound Rb-E2F protein acts as a negative regulator by inhibiting transcription CDKN2A, and therefore the functional inactivation of Rb by E7 thereby the transcriptional inhibition of the p16 gene is lost. HPV-positive tumours are consequently characterised by high expression of high levels of p16 [22]. p16 protein can be detected by technically simple immunohistochemistry, and since several studies have shown a very high correlation (>90%) to HPV-positively in oropharyngeal tumours, it has been suggested as a clinically useful surrogate marker [23, 24].

In head and neck cancer caused by the traditional risk factors, tobacco and alcohol, p53 is commonly mutated [25, 26] and 9p21-22 is lost early in carcinogenesis resulting in the loss of the tumour suppressing gene p16 [27]. In contrast, HPV-positive head and neck tumours have decreased expression of wild-type p53 due to the inactivation and degradation by the E6 oncoprotein. Furthermore, in a study by Westra et al. in 2008 [28] it was shown that HPV 16 and mutated 53 may coexist in a subset of head and neck squamous cell carcinoma but HPV 16 and disruptive p53 mutations seemed to be nonoverlapping events. An inverse relationship between HPV-16 infection and disrupted p53 gene mutations in head and neck carcinomas was suggested, and thus HPV positive head and neck tumours represent a distinct molecular phenotype with a unique mechanism of tumorigenesis independent of the mutagenic effect of tobacco and alcohol.

3. Risk Factors for HPV

In contrast to the HPV-negative cancers in the head neck region the vast majority of HPV-positive cancers lack association with the traditional risk factors, tobacco and alcohol [29]. Epidemiological studies on HPV-associated cervical cancer have clearly demonstrated that HPVs are transmitted by sexual contact [30] and today there are several studies suggesting that also HPV-positive head and neck tumours are sexually transmitted. It is assumed that HPV infection precedes the development of HPV positive head and neck cancers, and the presence of high-risk HPV infection on the oral mucosa and seropositivity increase the risk of development of head and neck cancers [13, 14, 31, 32]. Therefore risk factors for HPV oral infection are likely to be risk factors for HPV-positive head neck tumours. Oral HPV infections are rare in newborns of HPV-infected mothers and in children prior to sexual activity; infections increase after onset of sexual activity. In addition, an increased risk for tonsillar cancer among women with cervical lesions and a higher rate of tonsillar and tongue cancers among husbands of women with cervical dysplasia or cancer have been identified [33]. The risk of HPV-positive head and neck tumours has been associated with sexual behaviour including increasing numbers of both vaginal and oral sex partners, young age at first intercourse, and history of genital warts [34–37]. Also other life style factors like poor oral hygiene and marijuana use have been discussed and the most recent report found that the risk of developing an HPV-16 positive head and neck cancer increased with increased marijuana use but no correlation to oral hygiene was found [37]. Whether tobacco and alcohol increase the risk is not clear where some studies found no association to development of HPV-positive head neck cancers [13, 37] while others have found that thier use increase the risk [38]. Patients with the Fanconi anaemia have increased risk of HPV-mediated tumourigenesis [13] and some data indicate that HIV-patients have increased rates of HPV-related disease in the oral cavity despite antiretroviral therapy [39, 40].

4. Epidemiology

As for other head and neck cancers, the incidence of oropharyngeal cancer rates varies widely around the world and even within population significant differences have been observed. The black population in the United States, for instance, tends to have higher incidence rates than whites and hispanic populations all over the country. The SEER, Surveillance Epidemiology and End Results, covers approximately 14% of the US population and the age-standardized rates of tonsillar cancer in whites were 1.4 for men and 0.4 for women in 1993–1997. For blacks the rates were 2.9 and 0.6, per 100 000 person-years, respectively.

By contrast, in China, the rates of tonsillar cancer are generally low, for instance, in Beijing where the rates were 0.1 for men and 0.0 for women, respectively. Interestingly, in Hong Kong and in Taiwan, places with great western influence, the rates were 6 to 12 times higher than in Beijing. In India, with high rates of oral cancer, the rates of tonsillar cancer were between 0.8 and 2.8 in men and 0.2 and 0.5 in women, respectively.
In most countries the rates tend to be higher in males than in females with a ratio from 2:1 to 5:1. However, in the Philippines and in Vietnam women had higher incidence rates than men. Interestingly, this was true also for the Philippine population in California.

Also in Europe, the incidence rates show great variations with intranational variability in some countries. The highest rates were seen in parts of France, in Somme, where the rates were as high as 6.4 for men and 0.8 for women [41].

In several western countries, the incidence of oropharyngeal cancer has increased greatly in the last decades [7–9, 42–44] and the incidence has increased most in men. At the same time, the prevalence of HPV in those tumours has increased in a similar way indicating that HPV in fact is responsible for this increase [11, 42, 45]. HPV has been found in 45–95% of the oropharyngeal tumours [11, 42, 46] and the prevalence of HPV 16 has been quite homogenous around the world [47] in contrast to cervical cancer, where the prevalence of different types of HPV varies around the world [48].

5. HPV in Head-Neck Cancers

Apart from having a different epidemiology and aetiology, the HPV-positive oropharyngeal cancers also constitute a distinct subgroup clinopathologically. HPV-positive tumours are usually poorly differentiated and nonkeratinizing and have a basoid appearance in contrast to the HPV-negative that is more moderately differentiated and keratinizing [49, 50]. HPV-positive tumours also demonstrate significantly lower levels of chromosonal mutations than the HPV-negative tumours [51, 52]. Furthermore, patients with HPV-positive oropharyngeal cancers in general, especially tonsillar cancers, tend to be younger at time of diagnosis [42, 53], possibly with the exception of base of tongue cancers where no age difference could be found between the HPV-positive and HPV-negative cancer patients [10]. The majority of the patients have no prior history of tobacco and/or high alcohol consumption and have generally a better performance status compared to the HPV-negative patients [37, 54]. Moreover, HPV-positive tumours often present at a higher stage with a small T-size (T1–T2) [55] but frequently there is a large, often cystic, nodal involvement (N+) [56, 57], thus the HPV-positive tumours are often diagnosed in clinical advanced stages, that is, Stages III-IV [15].

6. Clinical Implications/Effect on Prognosis

The prognosis for HPV-positive oropharyngeal cancer patients is better than that for patients with HPV negative tumours independent of nodal status, age, stage, tumour differentiation, or gender [1, 15, 58–60]. Several studies have shown 80–95% 2-3 years overall survival rate for the HPV-positive patients compared to 57–62% for the HPV-negative subgroup of oropharyngeal tumours [60–62].

While it is still unclear whether tobacco is a risk factor for HPV-induced oropharyngeal tumors, it seems clear that smoking has a negative impact on relapse and survival for the HPV-positive tumours [63]. The risk of death and cancer relapse significantly increased by 1% for each additional pack year of tobacco smoking [61], indicating that the biological behaviour of an HPV-positive tumour may be altered by tobacco use.

Treatment of head and neck tumours today is often standardized and based on tumour stage despite the knowledge of the heterogeneity regarding tumour aggressiveness and response to treatment of the tumours varies greatly. Treatment of patients with advanced disease often includes both oncological and surgical treatment as both carry acute side effects and lifelong sequelae. The surgical trend in the last years, especially regarding neck dissection, has turned from a very radical operation towards more organ preserving selective/modified neck dissections when possible, reducing the morbidity. In contrast, the oncological treatment has turned in the opposite direction including the development of altered fractionation radiotherapy, integration of chemotherapy with radiotherapy, incorporation of intensity-modulated radiotherapy, and the introduction of targeted biological therapy. The combined modality treatment and the altered/intensified fractionation have improved outcome for head neck cancer patients in general [64, 65], but the morbidity has also significantly increased [66–68]. However, today there is no absolute consensus about patient selection for altered fractionation regimes, type of chemoradiotherapy association, radiation, or chemotherapy dose schedule. Among older patients with advanced disease, age over 70 years, the compliance to treatment is low due to significant comorbidity and poor performance [68]; thus this intense therapy is probably not suitable for this group of patients.

Patients with HPV-positive tumours in the oropharynx show an improved survival regardless of treatment strategy. Superior outcome for HPV-positive tumours has been shown for surgery [69], convectional and modified fractionated radiotherapy [55], induction chemotherapy [60], concurrent chemotherapy [61] and induction chemotherapy plus concurrent chemotherapy [60]. Thus, regarding patients with HPV-positive tumours in oropharynx the debate today is whether the intense therapy is too aggressive in this group of patients since they show a superior survival regardless of treatment strategies.

Strengthening this theory, a recent published study by Ang et al. [61] showed no significant difference in overall survival between a concomitant boost accelerated fraction regimen of radiotherapy and a standard fractionation regimen when combined with concurrent high-dose cisplatin for HPV-positive patients.

The reason for the better response to treatment for patients with HPV positive tumours is not known. There are studies that have found an inverse relationship between tumour HPV status and presence of p53 mutations in head and neck cancer [50, 70]. The improved response to oncological treatment observed for patients with HPV-positive tumours could therefore be explained by the presence of an intact p53-mediated apoptotic response in HPV-positive tumours. Another possibility is immunological factors related to HPV infection [71].
Today, there is a subgroup of the HPV-positive oropharyngeal cancers that have worse clinical outcome, that do not respond as well to given treatment, and have a higher rate of relapses and worse survival than the majority of the tumours in this group. A question for the future is how to separate the HPV-positive oropharyngeal tumours in this relative small group. Several potential clinical markers have been suggested, p16 [23, 24, 55, 72], Cyclin D1, [73], EGFR [74–76], p53 [28], and p21 [73], and maybe a combination of these and other not yet known markers may provide additional prognostic information and thus guide us to select the right patients for the right combination of treatment.

Based on the profound impact of HPV on the response to treatment for patients with oropharyngeal tumours, HPV-status should be included to standard pathological reporting in clinic and the planning of treatment strategies for this group of patients. Future clinical trials comprising patients with oropharyngeal tumours should include HPV status as a stratification factor in order to identify the least morbid treatment to cure this group of patients.

7. Concluding Remarks

HPV-positive oropharyngeal cancer is recognized as a distinct subset of head and neck squamous cell carcinoma with a favourable outcome. HPV status is a profound prognostic factor for overall and progression-free survival, treatment response, and tumour control. The superior outcome is independent of nodal status, age, stage, tumour differentiation, or gender and regardless of treatment strategy. The explanation for this difference is not clearly understood today and is probably a combination of several factors, patient-related (younger age, less exposed to tobacco and alcohol, less co-morbidity, etc.) as well as tumour-related factors (presence of p53-mediated apoptosis).

HPV-positive oropharyngeal tumours represent a distinct clinopathological profile where there still exist many questions to be answered regarding tumour biology and how the disease develops (tumourogenesis).

In future, clinical trials on oropharyngeal tumours need to take HPV-status in consideration. There is a possibility that less intense treatment strategies with lower rate of acute and long-term side effects do not compromise the survival outcome for this group of patients. Since patients with HPV-positive oropharyngeal cancers often are younger and in good health, few severe life-long complications are very important considerations. We need further knowledge about the tumour biology and identification of additional clinical useful markers to combine with HPV-status for appropriate risk stratification in future clinical trials in order to optimize the treatment for each individual patient in the future.

References

[1] M. L. Gillison, “Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity,” Seminars in Oncology, vol. 31, no. 6, pp. 744–754, 2004.

[2] F. Bray, R. Sankila, J. Ferlay, and D. M. Parkin, “Estimates of cancer incidence and mortality in Europe in 1995,” European Journal of Cancer, vol. 38, no. 1, pp. 99–166, 2002.

[3] D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.

[4] J. J. Pindborg, K. H. Zheng, C. R. Kong, and F. X. Lin, “Pilot survey of oral mucosa in areca (betel) nut chewers on Hainan Island of the People’s Republic of China,” Community Dentistry and Oral Epidemiology, vol. 12, no. 3, pp. 195–196, 1984.

[5] L. Licitra, J. Bernier, C. Grandi, M. Merlano, P. Bruzzi, and J. L. Lefèvre, “Cancer of the oropharynx,” Critical Reviews in Oncology/Hematology, vol. 41, no. 1, pp. 107–122, 2002.

[6] E. M. Sturgis and P. M. Cinciripini, “Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?” Cancer, vol. 110, no. 7, pp. 1429–1435, 2007.

[7] M. Frisch, H. Hjalgrim, A. B. Jæger, and R. J. Biggar, “Changing patterns of tonsillar squamous cell carcinoma in the United States,” Cancer Causes and Control, vol. 11, no. 6, pp. 489–495, 2000.

[8] C. H. Shiboski, B. L. Schmidt, and R. C. K. Jordan, “Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years,” Cancer, vol. 103, no. 9, pp. 1843–1849, 2005.

[9] L. Hammarstedt, D. Dahlstrand, D. Lindquist et al., “The incidence of tonsillar cancer in Sweden is increasing,” Acta Oto-Laryngologica, vol. 127, no. 9, pp. 988–992, 2007.

[10] P. Attner, J. Du, A. Näsmann et al., “The role of human papillomavirus in the increased incidence of base of tongue cancer,” International Journal of Cancer, vol. 126, no. 12, pp. 2879–2884, 2010.

[11] A. Näsmann, P. Attner, L. Hammarstedt et al., “Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?” International Journal of Cancer, vol. 125, no. 2, pp. 362–366, 2009.

[12] I. U. Doobaree, S. H. Landis, K. M. Linklater, I. El-Hariry, H. Moller, and J. Tyczynski, “Head and neck cancer in South East England between 1995–1999 and 2000–2004: an estimation of incidence and distribution by site, stage and histological type,” Oral Oncology, vol. 45, no. 9, pp. 809–814, 2009.

[13] G. D’Souza, A. R. Kreimer, R. Viscidi et al., “Case-control study of human papillomavirus and oropharyngeal cancer,” New England Journal of Medicine, vol. 356, no. 19, pp. 1944–1956, 2007.

[14] J. Mork, A. K. Lie, E. Glattre et al., “Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 344, no. 15, pp. 1125–1131, 2001.

[15] D. Lindquist, M. Romanitan, L. Hammarstedt et al., “Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7,” Molecular Oncology, vol. 1, no. 3, pp. 350–355, 2007.

[16] M. J. Strauss and E. W. Shaw, “Crystalline virus-like particles from skin papillomas characterized by intranuclear inclusion bodies,” Proceedings of the Society for Experimental Biology and Medicine, vol. 72, no. 1, pp. 46–50, 1949.

[17] E. M. De Villiers, C. Fauquet, T. R. Broker, H. U. Bernard, and H. Zur Hausen, “Classification of papillomaviruses,” Virology, vol. 324, no. 1, pp. 17–27, 2004.
[18] W. Deng, B. Y. Lin, GE. Jin et al., “Cyclin/CDK regulates the nucleocytoplasmic localization of the human papillomavirus E1 DNA helicase,” *Journal of Virology*, vol. 78, no. 24, pp. 13954–13965, 2004.

[19] A. R. Kreimer, G. M. Clifford, P. Boyle, and S. Franceschi, “Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 14, no. 2, pp. 467–475, 2005.

[20] C. H. Chung and M. L. Gillison, “Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications,” *Clinical Cancer Research*, vol. 15, no. 22, pp. 6758–6762, 2009.

[21] P. A. Havre, J. Yuan, L. Hedrick, K. R. Cho, and P. M. Glazer, “p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells,” *Cancer Research*, vol. 55, no. 19, pp. 4420–4424, 1995.

[22] J. R. Nevins, “The Rb/E2F pathway and cancer,” *Human Molecular Genetics*, vol. 10, no. 7, pp. 699–703, 2001.

[23] H. M. Dahlstrand, D. Lindquist, L. Björnestrål et al., “P16 INK4a correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma,” *Anticancer Research*, vol. 25, no. 6C, pp. 4375–4383, 2005.

[24] J. P. Klassmann, E. Gültekin, S. J. Weissenborn et al., “Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus,” *American Journal of Pathology*, vol. 162, no. 3, pp. 747–753, 2003.

[25] J. C. Ahomadegbe, M. Barrois, S. Fogel et al., “High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions,” *Oncogene*, vol. 10, no. 6, pp. 1217–1227, 1995.

[26] J. C. De Vicente, L. M. J. Gutiérrez, A. H. Zapatero, M. F. Forcelledo, G. Hernández-Vallejo, and J. S. López Arranz, “Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases,” *Head and Neck*, vol. 26, no. 1, pp. 22–30, 2004.

[27] S. H. Kim, B. S. Koo, S. Kang et al., “HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation,” *International Journal of Cancer*, vol. 120, no. 7, pp. 1418–1425, 2007.

[28] W. H. Westra, J. M. Taube, M. L. Poeta, S. Begum, D. Sidransky, and W. M. Koch, “Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck,” *Clinical Cancer Research*, vol. 14, no. 2, pp. 366–369, 2008.

[29] K. Lindel, K. T. Beer, J. Laisse, R. H. Greiner, and D. M. Aebersold, “Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma,” *Cancer*, vol. 92, no. 4, pp. 805–813, 2001.

[30] H. Zur Hausen, “Papillomaviruses and cancer: from basic studies to clinical application,” *Nature Reviews Cancer*, vol. 2, no. 5, pp. 342–350, 2002.

[31] E. M. Smith, J. M. Ritchie, K. F. Summersgill et al., “Human papillomavirus in oral exfoliated cells and risk of head and neck cancer,” *Journal of the National Cancer Institute*, vol. 96, no. 6, pp. 449–455, 2004.

[32] B. G. Hansson, K. Rosenquist, A. Antonsson et al., “Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden,” *Acta Oto-Laryngologica*, vol. 125, no. 12, pp. 1337–1344, 2005.

[33] K. Hemminki, C. Dong, and M. Frisch, “Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands,” *European Journal of Cancer Prevention*, vol. 9, no. 6, pp. 433–437, 2000.

[34] S. M. Schwartz, J. R. Daling, D. R. Doody et al., “Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection,” *Journal of the National Cancer Institute*, vol. 90, no. 21, pp. 1626–1636, 1998.

[35] K. Rosenquist, J. Wennerberg, E. B. Schildt, A. Bladström, B. Göran Hansson, and G. Andersson, “Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden,” *Acta Otolaryngologica*, vol. 125, no. 12, pp. 1327–1336, 2005.

[36] A. R. Kreimer, A. J. Alberg, R. Daniel et al., “Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus,” *Journal of Infectious Diseases*, vol. 189, no. 4, pp. 686–698, 2004.

[37] M. L. Gillison, G. D’Souza, W. Westra et al., “Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers,” *Journal of the National Cancer Institute*, vol. 100, no. 6, pp. 407–420, 2008.

[38] E. M. Smith, L. M. Rubenstein, T. H. Haugen, E. Hamiskyova, and L. P. Turek, “Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers,” *Cancer Causes and Control*, vol. 21, no. 9, pp. 1369–1378, 2010.

[39] M. Adamoupolou, E. Vairaktaris, V. Panis, E. Nkenke, F. W. Neukam, and C. Yapijakis, “HPV detection rate in saliva may depend on the immune system efficiency,” *In Vivo*, vol. 22, no. 5, pp. 599–602, 2008.

[40] J. Palefsky, “Human papillomavirus-related disease in people with HIV,” *Current Opinion in HIV and AIDS*, vol. 4, no. 1, pp. 52–56, 2009.

[41] D. M. Parkin, S. L. Whelan, J. Ferlay, L. Teppo, D. Thomas, and D. M. Thomas, *Cancer Incidence in Five Continents*, vol. 8, IARC, 2002.

[42] L. Hammarstedt, D. Lindquist, H. Dahlstrand et al., “Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer,” *International Journal of Cancer*, vol. 119, no. 11, pp. 2620–2623, 2006.

[43] D. I. Conway, D. L. Stockton, K. A. A. S. Warnakulasuriya, G. Ogden, and L. M. D. Macpherson, “Incidence of oral and oropharyngeal cancer in United Kingdom (1990–1999)—recent trends and regional variation,” *Oral Oncology*, vol. 42, no. 6, pp. 586–592, 2006.

[44] B. J. M. Braakhuis, O. Visser, and C. René Leemans, “Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults,” *Oral Oncology*, vol. 45, no. 9, pp. e85–e89, 2009.

[45] J. A. Ernst, C. G. Sciotto, M. M. O’Brien et al., “Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus,” *Laryngoscope*, vol. 117, no. 12, pp. 2115–2128, 2007.

[46] C. Fakhry and M. L. Gillison, “Clinical implications of human papillomavirus infection, and human papillomavirus type 16-negative head and neck cancers,” *Cancer Causes and Control*, vol. 21, no. 9, pp. 1369–1378, 2010.
[48] N. Muñoz, F. X. Bosch, S. De Sanjose et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003.

[49] S. P. Wilczynski, B. T. Y. Lin, Y. Xie, and I. B. Paz, “Detection of human papillomavirus DNA and oncogene overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma,” American Journal of Pathology, vol. 152, no. 1, pp. 145–156, 1998.

[50] M. L. Gillison, W. M. Koch, R. B. Capone et al., “Evidence for a causal association between human papillomavirus and a subset of head and neck cancers,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 709–720, 2000.

[51] B. J. M. Braakhuis, P. J. F. Snijders, W. J. H. Keun et al., “Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus,” Oncogene, vol. 25, no. 17, pp. 2558–2564, 2006.

[52] S. J. Smeets, B. J. M. Braakhuis, S. Abbas et al., “Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus,” Journal of the National Cancer Institute, vol. 96, no. 13, pp. 998–1006, 2004.

[53] E. M. Smith, J. M. Ritchie, K. F. Summersgill et al., “Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers,” International Journal of Cancer, vol. 108, no. 5, pp. 766–772, 2004.

[54] A. K. Chaturvedi, E. A. Engels, W. F. Anderson, and M. L. Gillison, “Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 612–619, 2008.

[55] P. Lassen, J. G. Eriksen, S. Hamilton-Dutoit, T. Tramm, J. Alsner, and J. Overgaard, “Effect of HPV-associated p16 expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1992–1998, 2009.

[56] D. Goldenberg, S. Begum, W. H. Westra et al., “Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon,” Head and Neck, vol. 30, no. 7, pp. 898–903, 2008.

[57] P. Lassen, “The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome,” Radiotherapy and Oncology, vol. 95, no. 3, pp. 371–380, 2010.

[58] H. Melin, S. Friesland, R. Lewensohn, T. Daliani, and E. Munck-Wikland, “Human papilloma virus (HPV) DNA in tonsillar cancer: clinical correlates, rate of relapse, and survival,” International Journal of Cancer, vol. 89, no. 3, pp. 300–304, 2000.

[59] P. M. Weinberger, Z. Yu, B. G. Haftty et al., “Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 736–747, 2006.

[60] C. Fakhry, W. H. Westra, S. Li et al., “Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 261–269, 2008.

[61] K. K. Ang, J. Harris, R. Wheeler et al., “Human papillomavirus and survival of patients with oropharyngeal cancer,” New England Journal of Medicine, vol. 365, no. 1, pp. 24–35, 2010.

[62] P. Attner, J. Du, A. Näsman et al., “The role of human papillomavirus in the increased incidence of base of tongue cancer,” International Journal of Cancer, vol. 126, no. 12, pp. 2879–2884, 2010.

[63] H. C. Hafkamp, J. J. Manni, A. Haesevoets et al., “Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas,” International Journal of Cancer, vol. 122, no. 12, pp. 2656–2664, 2008.

[64] J. P. Pignon, A. L. Maître, E. Maillard, and J. Bourhis, “Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients,” Radiotherapy and Oncology, vol. 92, no. 1, pp. 4–14, 2009.

[65] J. Bourhis, J. Overgaard, H. Audry et al., “Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis,” Lancet, vol. 368, no. 9538, pp. 843–854, 2006.

[66] M. Machtay, J. Moughan, A. Trott et al., “Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3582–3589, 2008.

[67] G. Sanguineti, A. Richetti, M. Bignardi et al., “Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 3, pp. 762–771, 2005.

[68] R. Corvò, “Evidence-based radiation oncology in head and neck squamous cell carcinoma,” Radiotherapy and Oncology, vol. 85, no. 1, pp. 156–170, 2007.

[69] L. Licitra, F. Perrone, P. Bossi et al., “High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5630–5636, 2006.

[70] M. Dai, G. M. Clifford, F. Le Calvez et al., “Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study,” Cancer Research, vol. 64, no. 2, pp. 468–471, 2004.

[71] W. C. Spanos, P. Nowicki, D. W. Lee et al., “Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer,” Archives of Otolaryngology—Head and Neck Surgery, vol. 135, no. 11, pp. 1137–1146, 2009.

[72] C. A. Fischer, I. Zlobec, E. Green et al., “Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?” International Journal of Cancer, vol. 126, no. 5, pp. 1256–1262, 2010.

[73] H. C. Hafkamp, J. J. Mooren, S. MH. Claessen et al., “P21 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis,” Modern Pathology, vol. 22, no. 5, pp. 686–698, 2009.

[74] B. Kumar, K. G. Cordell, J. S. Lee et al., “EGFR, p16, HPV titer, Bcl-xl and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3128–3137, 2008.

[75] N. Reimers, H. U. Kasper, S. J. Weissenthorn et al., “Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer,” International Journal of Cancer, vol. 120, no. 8, pp. 1731–1738, 2007.

[76] A. Hong, T. Dobbins, C. S. Lee et al., “Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer,” European Journal of Cancer, vol. 46, no. 11, pp. 2088–2096, 2010.